



PIONEERING NEW GENERATION Life-Science Products

OFER HAVIV | PRESIDENT & CEO

May, 2024



FORWARD LOOKING STATEMENT

This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, pipeline, as well as our capabilities and technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the current war between Israel, Hamas and Hezbollah and any worsening of the situation in Israel such as further mobilizations or escalation in the northern border of Israel and those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

AGENDA

- ★ About Evogene
- ★ Value Proposition
- ★ Business Strategy
- ★ Success Stories
- ★ Summary

Throughout History

HUMANS HAVE CONSISTENTLY INVESTED TIME AND RESOURCES IN THE PURSUIT OF IMPROVING LIFE, WELL-BEING, AND HEALTH, FUELED BY AN INNATE

DESIRE FOR
PROGRESS &
A BETTER **FUTURE**



DECODING BIOLOGY


OUR VISION

**PIONEER GROUNDBREAKING LIFE-
SCIENCE PRODUCTS ROOTED IN
MICROBES, SMALL MOLECULES,
AND GENOMICS**




DIVERSE LIFE-SCIENCE INDUSTRIES


MICROBES



SMALL MOLECULES



GENETIC ELEMENTS





THE COMPLEXITY

OF LIFE SCIENCE PRODUCT DEVELOPMENT

Low probability of success
with high cost and long
time-to market



Pharma Industry

Cost of developing a single
pharmaceutical drug*

In the 1970's

\$180M



In recent years

> \$2,000M



Ag-chemicals Industry

Years to develop a new crop
protection product**

1995

8Y

2000

9Y

2005-2008

10Y

2010-2014

11+Y

*Phillips McDougall, 2016.

**<https://www.forbes.com/sites/matthewherper/2017/10/16/the-cost-of-developing-drugs-is-insane-a-paper-that-argued-otherwise-was-insanely-bad/?sh=7533aa82d459>

THE RESOURCE KILLER

LIFE-SCIENCE PRODUCTS LONG-TAIL PROCESS

THE CHALLENGE


finding the winning candidates out of a vast number of possible prospects that address a complex myriad of criteria, to **reach higher success rate for products**

> DISCOVERY

> OPTIMIZATION


> DEVELOPMENT

> REGULATION




TODAY WE
ARE ON THE
BRINK OF A
**HISTORIC
SINGULARITY
POINT**

Computational technology advancements enable the **discovery** and **optimization** of the most promising candidates, addressing multiple development challenges towards successful life-science based products



LIFE-SCIENCE PRODUCT DEVELOPMENT





OUR

DECODING BIOLOGY

MISSION

WE MERGE LIFE-SCIENCE WITH BIG DATA AND CUTTING-EDGE AI TECHNOLOGIES TO **EFFECTIVELY DISCOVER AND OPTIMIZE BREAKTHROUGH LIFE-SCIENCE BASED PRODUCTS**

WHEN LIFE-SCIENCE MEETS DISRUPTIVE TECHNOLOGIES



ISRAEL
HQ

2002
Established

EVGN
NASDAQ
& TASE

135
Employees

30%
PhD's

50%
Women

3

Innovative AI
Tech Engines



4

Subsidiaries



COMMERCIAL PRODUCTS*

Bio-inoculant



Castor varieties



*By Evogene's subsidiaries



Investment &
Collaboration



Investment &
Collaboration



Collaboration



Collaboration



Collaboration



Collaboration



Investment



Collaboration



Collaboration



Collaboration



Collaboration



AGENDA

- ★ About Evogene
- ★ Value Proposition
- ★ Business Strategy
- ★ Success Stories
- ★ Summary

OUR SOLUTION

Breakthrough Products

Backed by Technology & Science

CPB  PLATFORM

Born from over a decade of intensive R&D, fueled by millions of dollars in investment, merging life-science with big- data and cutting-edge AI technology, the CPB directs and accelerates life-science product discovery and optimization through dedicated **AI Tech-Engines**.


CPB  | Computational Predictive Biology



WE DIRECT AND ACCELERATE LIFE-SCIENCE PRODUCT

DISCOVERY & OPTIMIZATION

utilizing **3** dedicated **AI tech-engines**



The Result:

Promising candidates addressing multiple development challenges towards successful life-science-based products.



AI TECH- ENGINES

Direct & accelerate life-science
product discovery & optimization

Discovery



Computational selection of the most promising candidates to initiate the product development process.




Optimization

Computational driven solution addressing optimization challenges for the selected candidates, without impairing their ability to address various other product attributes.


AI TECH-ENGINE DASHBOARD

(Example)




POTENTIAL MARKET DIVERSITY

Structuring an
'**ecosystem**' of diverse
product types to be
developed utilizing our
AI Tech-Engines



Potential Markets for *MicroBoost AI* (Example)




AGENDA

- ★ About Evogene
- ★ Value Proposition
- ★ **Business Strategy**
- ★ Success Stories
- ★ Summary


A WORLD OF OPPORTUNITIES FOR OUR AI TECH ENGINES




MICROBES



SMALL MOLECULES




GENETIC ELEMENTS



BUSINESS STRATEGY

Capture the value of our AI tech-engines through diverse collaborative partnerships to accelerate life-science product development

Partnering with experts in specific fields complements our technology, enabling groundbreaking innovations and financial gains for Evogene.



**MAXIMUM
POTENTIAL
MINIMUM
RISK**

BUSINESS MODEL

Two Main Partnership Structures

Capture the value of our AI tech-engines as product-development enablers, through:

LICENSING

A time-limited license grant for utilizing one of Evogene's tech-engines, to a related party for product development in a defined commercial field. In most cases the related party will be a subsidiary of Evogene.

COLLABORATION

Joint product development with a leading company utilizing Evogene's unique tech-engines. Typically, the partner leads later-stage development and product commercialization.



D1

Business Model

Licensing



Potential revenue stream

- License fees & R&D reimbursement
- Royalties from sale of end-products
- Dividends to Evogene as a shareholder*
- Significant one-time-payment upon an exit event**

Powered by



*Subject to meeting the Israeli dividend tests and criteria. May not be distributed in the near future or at all.

**As long as Evogene remains a major shareholder

02 Business Model

Collaboration



Potential revenue stream

- Upfront payments
- R&D fees
- Milestone payments
- Royalties from sale of end-products

Powered by



LICENSING & COLLABORATION | CURRENT STATUS

Licensing

Collaboration



MICROBES



Therapeutic microbes

- Immuno-oncology program
- GI related disorders



Microbials for crops

- Bio-stimulants
- Bio-pesticides



Probiotics

- Probiotics for Human Health



SMALL MOLECULES



Crop protection

- Herbicides
- Fungicides
- Insecticides



Pharmaceuticals

- Antimicrobial resistance (AMR)



GENETIC ELEMENTS

casterra

Castor for bio-based industries

- Elite castor seed varieties

FiNALLY Food

Food-tech

- Protein production in Plants for food-tech



Aquaculture

- Crustacean gene editing



Improved traits - canola

AGENDA

- ✦ About Evogene
- ✦ Value Proposition
- ✦ Business Strategy
- ✦ **Success Stories**
- ✦ Summary

MISSION

Improve food quality, sustainability and agricultural productivity through microbiome-based, **ag-biological products**

AG-BIOLOGICALS A RAPIDLY GROWING MARKET

The ag-biologicals market is expected to grow at a double digit CAGR over the next decade

UNIQUE AI TECH-PLATFORM AND DATA ASSETS

Proprietary tech platform increases probability of success and reduces cost and time-to-market

Powered by
 **Micro**
Boost^{AI}

BROAD & DIVERSE PIPELINE

8 programs under development; new product launch expected every 1-2 years

STRATEGIC INVESTORS & PARTNERS




2 REVENUE- GENERATING GRADUATED PROGRAMS




SOLD IN USA & CANADA**
& expanding globally



SUPERIOR PERFORMANCE
vs. alternatives




CONSISTENT PERFORMANCE



* Yalos™ has regulatory approval in the US & Canada for all small grains including wheat, barley, durum, oats, soybeans, canola, and others. Data was gathered in large side-by-side field trials in the US

** In 2023 Yalos™ was sold for wheat. 2023 trials for barley and durum look promising for potential 2024 expansion



Develop
Breakthrough Products



Increase
probability of success



Reduce
time and cost

Mission

To provide an integrated solution for Industrial cultivation of castor for bio-based industries

CASTOR OIL - EMERGING MARKET

A sustainable energy source, reducing the use of fossil fuels.

Global castor oil & oil derivatives market is expected to reach \$2.06 billion by 2028*
CAGR of 4.9%



UNIQUE TECH PLATFORM FOR ELITE SEED VARIETIES

Combining deep scientific know-how, genomic and phenotypic big-data, and computational technology for elite castor variety development

Powered by
Gene
Rator^{AI}

INTEGRATED AG-SOLUTION

Elite varieties suitable for mechanized farming, growing protocols, mechanized harvesting and dehulling solutions



STRATEGIC ALLIANCE

A strategic alliance in the biofuel space with ENI – a leading global oil & gas company



COMMERCIAL PRODUCTS

Proprietary varieties with improved traits suitable for commercial scale cultivation
EVF716, EVF712, EVF701





EVF716
Ricinus communis (castor beans) Quality Seeds EVF716

Variety Characteristics*		Technical Recommendations*	
Average plant height (cm)	70-120cm	Planting time	Early rainy season
Flowering (days from sowing)	35-40 days	Planting system	Pneumatic seeders
Total cycle (harvest) (days from sowing)	100-115 days	Spacing (conventional rows)	
Recume size	Small	Plants / Hecare (Density)	
Number of Recume	4-5 racemes	Seed consumption	
Stem color	Dark red	Seeding depth	
Drought tolerance	Low	*Variety characteristics are highly subjected to temperatures, soil salinity and water availability	
Oil content (%)	48-50%		
Grain yield potential (t/ha)	2-3 t/ha		

*Variety characteristics are highly subjected to temperatures, soil salinity and water availability

Cultivation*

Recommended herbicide	Pendimethalin
Hand weeding	Proceed when necessary
Fertilizers and liming	Follow local recommendation
Manual or mechanized harvesting	Farmer headers

*Variety characteristics are highly subjected to temperatures, soil salinity and water availability

Explore all Castor Varieties
EVF701 | EVF712

www.casterra.co



EVF712
Ricinus communis (castor beans) Quality Seeds EVF712

Variety Characteristics*		Technical Recommendations*	
Average plant height (cm)	100-150 cm	Planting time	Early - mid rainy season
Flowering (days from sowing)	40-45 days	Planting system	Pneumatic seeders
Total cycle (harvest) (days from sowing)	120-140 days	Spacing (conventional rows)	0.75-1 m among furrows
Recume size	Medium	Plants / Hecare (Density)	35-40k
Number of Recume	5-4 racemes	Seed consumption	10-14 kg/ha
Stem color	Light green	Seeding depth	~5cm
Drought tolerance	Medium	*Variety characteristics are highly subjected to temperatures, soil salinity and water availability	
Oil content (%)	48-50%		
Grain yield potential (t/ha)	2-3 t/ha		

*Variety characteristics are highly subjected to temperatures, soil salinity and water availability

Cultivation*

Recommended herbicide	Pendimethalin
Hand weeding	Proceed when necessary
Fertilizers and liming	Follow local recommendation
Manual or mechanized harvesting	Farmer headers

*Variety characteristics are highly subjected to temperatures, soil salinity and water availability


Explore all Castor Varieties
EVF701 | EVF716

www.casterra.co | info@casterra.co

Casterra Signs a Framework Agreement with a World Leading Oil and Gas Company to Sell Its Castor Seeds for Sustainable Biofuel Production, with Initial Purchase Orders of **\$9.1 Million**

Casterra is expected to deliver the initial orders of its proprietary castor seeds, developed using Evogene's GeneRator AI tech engine, during 2023

Rehovot, Israel – June 21, 2023 – Casterra Ag Ltd. ("Casterra"), an integrated castor cultivation solution company and a subsidiary of Evogene Ltd. ("Evogene") (Nasdaq: EVGN; TASE: EVGN), announced today that it signed a framework agreement to sell seeds of its proprietary castor varieties to one of the world's leading oil and gas companies for cultivation in specific African territories. Initial purchase orders, valued at an aggregate of \$9.1 million, were received and the seeds are expected to be delivered during 2023. Casterra's high-yield, high-oil castor seed varieties are optimized for biofuel production to support the growing market of sustainable energy.



Develop
Breakthrough Products



Increase
probability of success



Reduce
time and cost

AGENDA

- ✦ About Evogene
- ✦ Value Proposition
- ✦ Business Strategy
- ✦ Success Stories
- ✦ Summary

VISION

Pioneer groundbreaking life-science products rooted in microbe, small molecule, and genomics innovations.

MISSION


We merge scientific expertise with cutting-edge AI and big data technologies to discover and optimize innovative life-science products effectively.

OFFERING

3 dedicated AI Tech-Engines that efficiently direct and **accelerate** the development of **breakthrough** life-science products

BUSINESS STRATEGY

MAXIMUM POTENTIAL, MINIMUM RISK



EVOGENE GROUP'S PRODUCTS & PARTNERSHIPS

Bio-inoculant

Yalos™
INOCULANT

Castor varieties

 EVF701
 EVF712
 EVF716





THANK YOU

Annex I

FINANCIAL

OVERVIEW

KEY FINANCIALS: BALANCE SHEET

Key Points:

- Consolidated cash position: **~\$26.6** million as of 31.03.2024
- No** bank debt

Thousands of US \$	31.03.2024	31.12.2023
Current Assets	31,022	34,469
Long-Term Assets	15,758	16,632
Total Assets	46,780	51,101
Current Liabilities	6,129	6,944
Long-Term Liabilities (inc. ~\$10m convertible SAFE at Lavie Bio)	15,268	15,472
Equity attributable to equity holders of the Company	8,289	12,053
Non-controlling interest	17,094	16,632
Total Liabilities & Shareholders Equity	46,780	51,101

KEY FINANCIALS: BALANCE SHEET

Key Points:

- Q1 2024 revenue: **\$4.2M** vs. **\$0.6M** in Q1 2023; anticipating continued growth in 2024.
- Q1 2024 net loss: **\$3.8M** vs. **\$7.0M** in Q1 2023.
- Projected 2024 cash usage, excluding Lavie Bio and Biomica: **\$8.0M**, down **36%** from **\$12.5M** in 2023.

Thousands of US \$	1-3/2024	1-3/2023
Revenues	4,190	641
Cost of revenues	310	322
Gross profit	3,880	319
Research and development, net	4,801	4,800
Sales and marketing	992	800
General and administrative	1,654	1,515
Other expenses	519	-
Total operating expenses, net	7,966	7,115
Operating loss	(4,086)	(6,796)
Financing income (expenses), net	241	(230)
Loss before taxes on income	(3,845)	(7,026)
Tax benefit	-	(45)
Loss	(3,845)	(6,981)



Annex II

EVOGENE

SUBSIDIARIES

The Casterra logo features the word "casterra" in a dark blue, lowercase, sans-serif font. A small orange dot is positioned above the letter "a".

CASTOR OIL PRODUCTION

CASTERRA'S MISSION:

To provide an integrated solution for industrial cultivation of castor for bio-based industries

2008

Established

6

Production sites

IL

HQ
R&D

>3000

Seed lines

>1000MT

Seed
production

3

Commercial
products

**CURRENT
PARTNERS**



Collaboration

Powered by



Expected Value Drivers

- Expanding the seed production operations in several sites in Africa & Latin America, to fulfill all existing orders
- Strategic alliances – extending the collaboration frame in the biofuel space – more territories and new global partners
- Developing castor varieties that meet commercially valuable traits for the Biodiesel and Sustainable Aviation Fuel (SAF) industries
- Improving mechanical harvesting solutions through collaborations with global machinery companies

Latest News

BACK



Ag Biologicals

LAVIE BIO'S MISSION:

Improve food quality, sustainability and agriculture productivity through microbiome based, AI-driven, ag-biological products

2019

Established

25

Employees

IL

HQ

7

Products in development

1

Commercial product

IL, US & EU

R&D

CURRENT PARTNERS



Investment & Collaboration



Investment & Collaboration



Collaboration



Collaboration

Powered by



Expected Value Drivers

BIO-PESTICIDES

- LAV311 - US regulatory approval for bio-fungicide candidate for fruit rots – expected by 2024
- LAV321 - submission for Lavie Bio's bio-fungicide candidate for downy mildew to the US EPA for regulatory approval – expected by 2025
- Co-development and licensing agreement for an additional bio-pesticide program with a large multinational company – expected by 2025

BIO-STIMULANTS

- Yalos™ – distribution licensing agreements and sales expansion in USA & Canada. Expansion to additional crops and an additional territory in 2025

Latest News

BACK



Human Microbiome

BIOMICA'S MISSION:

Discovery and development of novel microbiome-based therapeutics for human disorders, utilizing cutting edge computational capabilities

2017

Established

20

Employees

IL

HQ
R&D

1

Leading program -
phase 1

3

Programs - clinical
/preclinical stage

\$20M

Recent financing
round

**CURRENT
PARTNERS**



Investment

Powered by



Expected Value Drivers

IMMUNO-ONCOLOGY

- Readout & completion of POC from first in-human study in 2024
- Initiation of phase 2 in 2025

IBD

- Clinical batch production of drug candidate for IBD as preparation for Phase 1 clinical trials in USA, in 2024

IBS

- Advancement of pre-clinical studies and nomination of bacterial consortium for clinical trial

Latest News

BACK



AG-CHEMICALS

AGPLENUS' MISSION:

Design next-generation, effective, and sustainable crop protection products by leveraging predictive chemistry and biology

2018

Established

13

Employees

IL

HQ
R&D

5

Programs under
development

3

Programs under
collaboration

2

Strategic
partners

**CURRENT
PARTNERS**



Collaboration



Collaboration

Powered by



Expected Value Drivers

HERBICIDES

- Corteva collaboration - achieve 2nd milestone
- Bayer collaboration - design additional molecules

FUNGICIDES

- Identification of 2 selected novel targets
- Generate HITs for the selected targets

Latest News

BACK